Eli Lilly, WuXi AppTec and Schrodinger were among the investors in the cardiovascular, pulmonary and metabolic disorder drug developer's latest round.

China-based computational therapeutics developer ShouTi raked in $100m on Wednesday in a series B round featuring drug development software provider Schrodinger and pharmaceutical firms WuXi AppTec and Eli Lilly.

Private investment partnership BVF Partners led the round, which included F-Prime Capital Partners and Eight Roads, both investing on behalf of investment and financial services group Fidelity.

Casdin Capital, Monashee Capital, Sage Partners, Stork Capital, Surveyor Capital, TCG X, Woodline Partners, Qiming Venture Partners, Terra Magnum Capital Partners, Sequoia Capital China…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Fernando Moncada Rivera

Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
Email LinkedIn